In DLBCL cells lacking NOXA amplification, BCL2 inhibition was associated with an increase in MCL1 protein abundance in a BIM-dependent manner, causing a decreased antilymphoma efficacy. The gene discussed is BCL2L11; the disease is diffuse large B-cell lymphoma.